Lin T-C, Chen S-U, Chen Y-F, Chang Y-C & Lin C-W
(2012) Histopathology 60, 287–295
Intramucosal variant of nasal natural killer (NK)/T cell lymphoma has a better survival than does invasive variant: implication on loss of E26 transformation-specific sequence 1 (ETS-1) and T-box expressed in T cells (T-bet) with invasion

Aims: Nasal natural killer/T cell lymphoma (NNKTCL) arises from the nasal mucosa, and spreads to adjacent tissues via local invasion or to regional lymph nodes and distant sites via metastasis. The aims of this study were to determine the impact of invasion on the prognosis of NNKTCL, and correlate invasion with the expression of cytotoxic markers of lymphoma cells.

Methods and results: Histopathological evaluations of invasion and immunohistochemistry for cytotoxic markers, including E26 transformation-specific sequence 1 (ETS-1), T-box expressed in T cells (T-bet), signal transducer and activator of transcription (STAT-1), CD56 and granzyme B (GB), were performed in 64 NNKTCLs. There were 17 stage I cases without invasion (stage Ia or intramucosal), 21 stage I cases with invasion (stage Ib), 16 stage II cases and 10 stages III/IV cases. Stage Ia NNKTCLs had a better 5-year overall survival rate than that of stages Ib, II or III/IV NNKTCLs (85%, 38%, 33% and 20%, respectively, P < 0.001 by log-rank test). Loss of ETS-1 was found in 24% (four of 17) stage Ia NNKTCLs and in 65% (28 of 43) stages Ib/II/III/IV NNKTCLs (P = 0.04, Fisher’s exact test); loss of T-bet was found in 29% (five of 17) stage Ia NNKTCLs and in 67% (30 of 45) stages Ib/II/III/IV NNKTCLs (P = 0.02, Fisher’s exact test).

Conclusions: NNKTCL is classically an aggressive lymphoma, but the intramucosal variant is less aggressive. Loss of ETS-1 or T-bet correlated weakly with invasion, a finding that requires further confirmation.

References

1 Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005; 19; 2186–2194.
10.1038/sj.leu.2403955
CAS PubMed Web of Science® Google Scholar
2 Liang X, Graham DK. Natural killer cell neoplasms. Cancer 2008; 112; 1425–1436.
10.1002/cncr.23316
CAS PubMed Web of Science® Google Scholar
3 Kim TM, Park YH, Lee SY et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 2005; 106; 3785–3790.
10.1182/blood-2005-05-2056
CAS PubMed Web of Science® Google Scholar
4 Lee J, Suh C, Park YH et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J. Clin. Oncol. 2006; 24; 612–618.
10.1200/JCO.2005.04.1384
PubMed Web of Science® Google Scholar
5 Swerdlow SH, Campo E, Harris NL et al. Tumours of haematopoietic and lymphoid tissues, WHO classiﬁcation of tumours. Lyon: IARC Press, 2008.
Google Scholar
6 Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 2006; 20; 123–137.
10.1016/j.blre.2005.10.001
CAS PubMed Web of Science® Google Scholar
7 Lieto LD, Borrego F, You CH et al. Human CD94 gene expression: dual promoters differing in responsiveness to IL-2 or IL-15. J. Immunol. 2003; 171; 5277–5286.
10.4049/jimmunol.171.10.5277
CAS PubMed Web of Science® Google Scholar
8 Shnyreva M, Weaver WM, Blanchette M et al. Evolutionarily conserved sequence elements that positively regulate IFN-gamma expression in T cells. Proc. Natl Acad. Sci. U S A 2004; 101; 12622–12627.
10.1073/pnas.0400849101
CAS PubMed Web of Science® Google Scholar
9 Djuretic IM, Levanon D, Negreanu V et al. Transcription factors T-bet and Runx3 cooperate to activate IFNg and silence IL4 in T helper type 1 cells. Nat. Immunol. 2007; 2; 145–153.
10.1038/ni1424
CAS Web of Science® Google Scholar
10 Afkarian M, Sedy JR, Yang J et al. T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat. Immunol. 2002; 3; 549–557.
10.1038/ni794
CAS PubMed Web of Science® Google Scholar
11 Yang Y, Ochando JC, Bromberg JS et al. Identification of a distant T-bet enhancer responsive to IL-12/Stat4 and IFNγ/Stat1 signals. Blood 2007; 110; 2494–2500.
10.1182/blood-2006-11-058271
CAS PubMed Web of Science® Google Scholar
12 Reeves RK, Gillis J, Wong FE et al. CD16– natural killer cells: enrichment in mucosal and secondary lymphoid tissues and altered function during chronic SIV infection. Blood 2010; 115; 4439–4446.
10.1182/blood-2010-01-265595
CAS PubMed Web of Science® Google Scholar
13 Lin CW, Chen YH, Chuang YC et al. CD94 transcripts imply a better prognosis in nasal-type extranodal NK/T-cell lymphoma. Blood 2003; 102; 2623–2631.
10.1182/blood-2003-01-0295
CAS PubMed Web of Science® Google Scholar
14 Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982; 5; 649–655.
10.1097/00000421-198212000-00014
CAS PubMed Web of Science® Google Scholar
15 Carbone PP, Kaplan HS, Musshoff K et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971; 31; 1860–1861.
CAS PubMed Web of Science® Google Scholar
16 Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl Cancer Inst. 2000; 92; 205–216.
10.1093/jnci/92.3.205
CAS PubMed Web of Science® Google Scholar
17 Cong P, Raffeld M, Teruya-Feldstein J et al. In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. Blood 2002; 99; 3376–3382.
10.1182/blood.V99.9.3376
CAS PubMed Web of Science® Google Scholar
18 Staudt LM. A closer look at follicular lymphoma. N. Engl. J. Med. 2007; 356; 741–742.
10.1056/NEJMcibr067155
CAS PubMed Web of Science® Google Scholar
19 Azab MB, Henry-Amar M, Rougier P et al. Prognostic factors in primary gastrointestinal non-Hodgkin’s lymphoma. A multivariate analysis, report of 106 cases, and review of the literature. Cancer 1989; 64; 1208–1217.
10.1002/1097-0142(19890915)64:6<1208::AID-CNCR2820640608>3.0.CO;2-Z
PubMed Web of Science® Google Scholar
20 El-Zahabi LM, Jamali FR, El-Hajj II et al. The value of EUS in predicting the response of gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication. Gastrointest. Endosc. 2007; 65; 89–96.
10.1016/j.gie.2006.05.009
PubMed Web of Science® Google Scholar
21 Mehra M, Agarwal B. Endoscopic diagnosis and staging of mucosa-associated lymphoid tissue lymphoma. Curr. Opin. Gastroenterol. 2008; 24; 623–626.
10.1097/MOG.0b013e32830bf80f
PubMed Web of Science® Google Scholar
22 Chott A, Dragosics B, Radaszkiewicz T. Peripheral T-cell lymphoma of the intestine. Am. J. Pathol. 1992; 141; 1361–1371.
PubMed Web of Science® Google Scholar
23 van de Water JM, Cillessen SA, Visser OJ et al. Enteropathy associated T-cell lymphoma and its precursor lesions. Best Pract. Res. Clin. Gastroenterol. 2010; 24; 43–56.
10.1016/j.bpg.2009.11.002
PubMed Web of Science® Google Scholar
24 Spencer J, Cerf-Bensussan N, Jarry A et al. Enteropathy-associated T cell lymphoma (malignant histiocytosis of the intestine) is recognized by a monoclonal antibody (HML-1) that defines a membrane molecule on human mucosal lymphocytes. Am. J. Pathol. 1988; 132; 1–5.
10.1002/path.1711560102
CAS PubMed Web of Science® Google Scholar
25 Verbeek WH, Goerres MS, von Blomberg BM et al. Flow cytometric determination of aberrant intraepithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. Clin. Immunol. 2008; 126; 48–56.
10.1016/j.clim.2007.09.002
CAS PubMed Web of Science® Google Scholar
26 Chinen H, Matsuoka K, Sato T et al. Lamina propria c-kit+ immune precursors reside in human adult intestine and differentiate into natural killer cells. Gastroenterology 2007; 133; 559–573.
10.1053/j.gastro.2007.05.017
CAS PubMed Web of Science® Google Scholar
27 Freud AG, Yokohama A, Becknell B et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. J. Exp. Med. 2006; 203; 1033–1043.
10.1084/jem.20052507
CAS PubMed Web of Science® Google Scholar
28 Dittmer J. The biology of the Ets1 proto-oncogene. Mol. Cancer 2003; 2; 29.
10.1186/1476-4598-2-29
PubMed Google Scholar
29 Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene 2003; 303; 11–34.
10.1016/S0378-1119(02)01156-3
CAS PubMed Web of Science® Google Scholar
30 Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur. J. Cancer 2005; 41; 2462–2478.
10.1016/j.ejca.2005.08.013
CAS PubMed Web of Science® Google Scholar
31 Barton K, Muthusamy N, Fischer C et al. The Ets-1 transcription factor is required for the development of natural killer cells in mice. Immunity 1998; 9; 555–563.
10.1016/S1074-7613(00)80638-X
CAS PubMed Web of Science® Google Scholar
32 Walunas TL, Wang B, Wang CR et al. Cutting edge: the Ets1 transcription factor is required for the development of NK T cells in mice. J. Immunol. 2000; 164; 2857–2860.
10.4049/jimmunol.164.6.2857
CAS PubMed Web of Science® Google Scholar
33 Wilson V, Conlon FL. The T-box family. Genome Biol. 2002; 3; 3008.1–3008.7.
10.1186/gb-2002-3-6-reviews3008
Google Scholar
34 Naiche LA, Harrelson Z, Kelly RG et al. T-box genes in vertebrate development. Annu. Rev. Genet. 2005; 39; 219–239.
10.1146/annurev.genet.39.073003.105925
CAS PubMed Web of Science® Google Scholar
35 Szabo SJ, Kim ST, Costa GL et al. A novel transcription factor, T-bet, diValpha14i NKT cells. Cell 2000; 100; 659–669.
10.1016/S0092-8674(00)80702-3
Web of Science® Google Scholar
36 Townsend MJ, Weinmann AS, Matsuda JL et al. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity 2004; 20; 477–494.
10.1016/S1074-7613(04)00076-7
CAS PubMed Web of Science® Google Scholar
37 Grenningloh R, Kang BY, Ho IC. Ets-1, a functional cofactor of T-bet, is essential for Th1 inflammatory responses. J. Exp. Med. 2005; 201; 615–626.
10.1084/jem.20041330
CAS PubMed Web of Science® Google Scholar
38 Takeuchi K, Yokoyama M, Ishizawa S et al. Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood 2010; 116; 5631–5637.
10.1182/blood-2010-06-290650
CAS PubMed Web of Science® Google Scholar
39 Mansoor A, Pittaluga S, Beck PL et al. NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathological features and follow-up in a unique case series. Blood 2010; 117; 1447–1452.
10.1182/blood-2010-08-302737
CAS PubMed Web of Science® Google Scholar
40 Lin CW, Lee WS, Chang CL, Yang JY, Hsu SM. Restricted KIR repertoire without TCR rearrangement defines a true NK cell lineage in a subset of sinonasal lymphoma. Am. J. Pathol. 2001; 159; 1671–1679.
10.1016/S0002-9440(10)63014-3
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume60, Issue2

January 2012

Pages 287-295

Intramucosal variant of nasal natural killer (NK)/T cell lymphoma has a better survival than does invasive variant: implication on loss of E26 transformation-specific sequence 1 (ETS-1) and T-box expressed in T cells (T-bet) with invasion

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Intramucosal variant of nasal natural killer (NK)/T cell lymphoma has a better survival than does invasive variant: implication on loss of E26 transformation-specific sequence 1 (ETS-1) and T-box expressed in T cells (T-bet) with invasion

Abstract

References

Citing Literature

References

Related

Information